3,791 companies
2,409 AI summaries
1,867 risk analyses
1,334 growth scores
Register free — watchlist & alerts →
🔔 Get free email alerts on Yuki Gosei Kogyo Co.,Ltd. (4531)
AI summaries of Japanese EDINET filings — in English. Free, unsubscribe anytime.
- ✓ Email alert when 4531 files its next EDINET disclosure
- ✓ AI summary · sentiment · risk · growth (JA / EN)
- ✓ Free account: watchlist & alerts on all the stocks you follow
EDINET 4531 Neutral Risk Analyzed 📈 Growth 3/10
Yuki Gosei Kogyo Co.,Ltd.
Annual Securities Report - 106th Term(2025/04/01 - 2026/03/31) / 2026-06-23 11:24
Covers EDINET statutory filings (TDNET timely disclosures / earnings flashes are not included).
EarningsGuidance DownDemandMarginNew MarketCapacity
AI Summary
2026-06-23 11:32
Revenue reached ¥15,448M (+2.1% YoY), marking 7 consecutive years of record highs, but operating profit dropped sharply to ¥383M (-68.4%) due to depreciation of new amino acid equipment and deteriorating margins in electronic materials products. FY2027 profit guidance remains unset pending clarity on Middle East impact.
KEY POINTS
- 7-year revenue record but massive 68.4% OP decline; new equipment depreciation and market weakness in electronic materials segment drove profit fall
- Rapid price and market share erosion in electronic materials-related products severely impacted Q4 profitability
- FY2027 outlook: strong revenue expected but profit targets remain undefined due to difficulty quantifying Middle East impact
📊 Revenue
Revenue +2.1% (¥15,128M → ¥15,448M)
💰 Operating profit
OP -68.4% (¥1,208M → ¥383M)
🔮 Outlook
FY2027: expect sustained strong revenue; profit targets (operating/ordinary/net) undefined pending Middle East geopolitical clarity. Mid-term plan targets: FY2027 ¥16.0B, FY2028 ¥16.5B, FY2029 ¥17.5B
📈 Growth outlook
📈 Growth 3/10
Revenue expected to remain solid backed by buoyant demand, but profit growth constrained by depreciation burden and intensifying competition. Mid-term targets suggest ~16% cumulative revenue growth over 3 years, but near-term margin recovery remains challenging.
Growth drivers
- Strong pharmaceutical-grade amino acid sales maintaining robust demand momentum
- Growing polymer materials and tire cord adhesive precursor sales in chemicals segment
- Mid-term strategy pursuing CDMO business expansion and new high-margin ventures
- Global supply chain strengthening and supply-chain resilience efforts to enhance competitiveness
Risk and growth scores and tags are AI-generated estimates from analyzing the disclosure. They are not guarantees of fact, nor investment advice or recommendations. Make investment decisions at your own discretion.
⚠️ Extracted Risk Factors
| Category | Description | Score | New |
|---|---|---|---|
| Customer Concentration Risk | Top 10 customers represent 68.8% of revenue. Sudden shifts in contract terms or termination by these major customers could materially impact financial performance. | 8/10 | |
| Raw Material Risk | Raw material costs exposed to crude oil/naphtha price fluctuations and Middle East geopolitical risks. Cost inflation could significantly compress margins. | 8/10 | |
| Business Performance Risk | Electronic materials product prices and market share are declining rapidly in the chemicals segment. Similar weakness could spread to other product lines. | 7/10 | |
| Disaster Risk | Single production facility in Iwaki, Fukushima. Earthquake, fire, or other natural disaster could halt operations with no backup capacity. | 7/10 | |
| Intensified Competition Risk | Food additive segment faces intensified price competition due to improved quality of foreign products. Ongoing pricing pressure requires continuous cost mitigation. | 6/10 | |
| Credit Risk | ¥4.5B syndicated loan carries financial covenants; consecutive operating losses trigger land/building collateral requirements. Additional commitment facilities also in place. | 6/10 | |
| Inventory Valuation Risk | Sharp market shifts could trigger sudden price declines or inventory obsolescence, requiring write-downs. | 5/10 | |
| Regulatory Risk | Pharmaceutical and food additive manufacturing faces risk from regulatory changes or stricter manufacturing standards. | 5/10 |
8/10
Customer Concentration Risk
Top 10 customers represent 68.8% of revenue. Sudden shifts in contract terms or termination by these major customers could materially impact financial performance.
8/10
Raw Material Risk
Raw material costs exposed to crude oil/naphtha price fluctuations and Middle East geopolitical risks. Cost inflation could significantly compress margins.
7/10
Business Performance Risk
Electronic materials product prices and market share are declining rapidly in the chemicals segment. Similar weakness could spread to other product lines.
7/10
Disaster Risk
Single production facility in Iwaki, Fukushima. Earthquake, fire, or other natural disaster could halt operations with no backup capacity.
6/10
Intensified Competition Risk
Food additive segment faces intensified price competition due to improved quality of foreign products. Ongoing pricing pressure requires continuous cost mitigation.
6/10
Credit Risk
¥4.5B syndicated loan carries financial covenants; consecutive operating losses trigger land/building collateral requirements. Additional commitment facilities also in place.
5/10
Inventory Valuation Risk
Sharp market shifts could trigger sudden price declines or inventory obsolescence, requiring write-downs.
5/10
Regulatory Risk
Pharmaceutical and food additive manufacturing faces risk from regulatory changes or stricter manufacturing standards.
Track Japanese disclosures with JSIGNAL
AI summaries, risk & growth analysis, watchlist alerts and a screener for every Japanese listed company.
Start free — 30-day trial Login